Like the iodinated contrast media used in computed tomography (CT), the gadolinium contrast applied in magnetic resonance imaging (MRI) studies have a plasma half-life ("in the blood") of approximately 2 hours and are almost completely eliminated from the bloodstream in patients with normal renal function within 24 hours.

Equally similar to computed tomography (iodinated) contrast media, the resonance contractor (gadolinium) is excreted in breast milk. However, it is likely that most of the gadolinium excreted in breast milk is in its stable form.

For better understanding, in rough statistical terms, less than 0.04% of the intravascular dose ("in the vein") of contrast administered to the mother is excreted in breast milk within the first 24 hours. Noting that less than 1% of the contrast medium ingested by the infant is absorbed through the gastrointestinal tract ("through the baby's gut"). Therefore, the expected systemic dose absorbed by the infant through breast milk is less than 0.0004% of the total dose administered to the mother. Thus, the amount ingested by the baby is much smaller than the allowable dose for use in newborns. Thus the likelihood of an adverse effect of such a small fraction of gadolinium absorbed from breast milk is remote .